Flashpoint Therapeutics’ Scientific Founder Chad A. Mirkin Awarded the Prestigious Harvey Prize

Audio By Carbonatix

EVANSTON, Ill.--(BUSINESS WIRE)--Dec 8, 2025--

Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today congratulates its scientific co-founder, Professor Chad A. Mirkin, on being awarded the Harvey Prize in Science and Technology. The prestigious international prize, awarded by the Technion, Israel Institute of Technology in Haifa, recognizes Professor Mirkin for groundbreaking discoveries that have fundamentally reshaped the fields of nanoscience and nanotechnology.

The Harvey Prize is the Technion's most esteemed scientific honor, recognizing individuals for exceptional achievements in technology and human health and for significant contributions to humanity. Notably, more than 30% of Harvey Prize recipients have subsequently been awarded the Nobel Prize. The award specifically honors Mirkin for exceptional achievements in technology and human health and for his significant contributions to humanity. Mirkin invented and developed spherical nucleic acids (SNAs), the core technology underpinning Flashpoint’s therapeutic platform.

SNAs are a revolutionary class of nanomedicines, and their discovery established the field of structural nanomedicine, where the architecture of a therapeutic, not just its chemical composition, dictates its efficacy and safety. This is the guiding principle behind Flashpoint’s mission to develop a new generation of precision medicines. The Harvey Prize is a testament to the power and potential of this approach, which is being leveraged by Flashpoint to create novel therapies for cancer and other devastating diseases.

“We are immensely proud to see Professor Mirkin receive this well-deserved and distinguished honor,” said Barry Labinger, Chief Executive Officer of Flashpoint Therapeutics. “The Harvey Prize is a powerful, independent validation of the scientific foundation upon which Flashpoint is built. Chad’s visionary work in creating SNAs and establishing the principles of structural nanomedicine provides us with a unique and powerful platform to develop life-changing therapeutics. We celebrate this remarkable achievement and are more energized than ever to translate this transformative science into clinical reality for patients.”

Professor Mirkin is the George B. Rathmann Professor of Chemistry and the Director of the International Institute for Nanotechnology (IIN) at Northwestern University. His work has led to seven SNA-based therapeutics currently in human clinical trials and more than 1,800 commercial products used worldwide.

“The Harvey Prize is a career-defining milestone, and I am honored to be among the extraordinary list of previous winners,” said Professor Mirkin. “I am grateful for the recognition from the Technion and for the dedicated efforts of my colleagues and trainees who have made this progress possible. It is thrilling to see the foundational science of SNAs being advanced by Flashpoint Therapeutics to address significant unmet medical needs.”

About Flashpoint Therapeutics

Flashpoint Therapeutics is a clinical-stage biotechnology company developing a new class of precision-engineered structural nanomedicines. Our platform enables the creation of targeted therapies that co-deliver optimized combinations of therapeutic components directly to individual cells, enhancing drug delivery, stability, potency, and safety. This modular approach supports a broad range of therapies, encompassing modalities like mRNA, DNA, proteins, and CRISPR. The company’s proprietary discovery platform is founded on nanotechnology research developed over the past decade at the laboratory of Prof. Chad Mirkin, Director of the International Institute for Nanotechnology at Northwestern University. Through strategic licensing and acquisition transactions with Northwestern University, Holden Pharmaceuticals, and Exicure, Flashpoint has assembled more than 150 issued patents and patent applications covering nucleic acid, protein, and CRISPR gene editing therapeutics. The company is funded by key investors, including Beta Lab and CS Venture Opportunities Fund. The company has also established an important partnership with King Abdullah International Medical Research Center (KAIMRC), which will advance the technology platform via the Flashpoint-KAIMRC Center of Excellence in Structural Nanomedicine and clinical trials in Saudi research institutions.

For more information about Flashpoint Therapeutics, please visit www.flashpoint.bio.

View source version on businesswire.com:https://www.businesswire.com/news/home/20251208557292/en/

CONTACT: Media Relations:

Rosie Gonzalez

[email protected]

847-922-9385

KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH TECHNOLOGY TECHNOLOGY NANOTECHNOLOGY RADIOLOGY PHARMACEUTICAL ONCOLOGY GENERAL HEALTH MEDICAL DEVICES GENETICS CLINICAL TRIALS SCIENCE BIOTECHNOLOGY OTHER SCIENCE HEALTH RESEARCH

SOURCE: Flashpoint Therapeutics

Copyright Business Wire 2025.

PUB: 12/08/2025 01:09 PM/DISC: 12/08/2025 01:10 PM

http://www.businesswire.com/news/home/20251208557292/en